Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last $6.71 USD
Change Today -0.09 / -1.32%
Volume 368.8K
OSUR On Other Exchanges
Symbol
Exchange
NASDAQ GS
Frankfurt
As of 8:10 PM 04/24/15 All times are local (Market data is delayed by at least 15 minutes).

orasure technologies inc (OSUR) Snapshot

Open
$6.78
Previous Close
$6.80
Day High
$6.94
Day Low
$6.68
52 Week High
12/22/14 - $10.93
52 Week Low
05/9/14 - $5.78
Market Cap
383.2M
Average Volume 10 Days
398.3K
EPS TTM
$-0.15
Shares Outstanding
57.1M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for ORASURE TECHNOLOGIES INC (OSUR)

orasure technologies inc (OSUR) Related Businessweek News

No Related Businessweek News Found

orasure technologies inc (OSUR) Details

OraSure Technologies, Inc., together with its subsidiaries, develops, manufactures, markets, and sells oral fluid diagnostic products and specimen collection devices in the United States, Europe, and internationally. The company also offers other diagnostic products, such as immunoassays and other in vitro diagnostic tests that are used on other specimen types. Its primary products include OraQuick ADVANCE HIV-1/2, OraQuick In-Home HIV Test, OraQuick HCV, OraSure QuickFlu rapid flu A&B test, OraSure, Oragene DX, Oragene DNA, Oragene RNA, ORAcollect, OMNIgene DISCOVER, Performagene LIVESTOCK and Oragene ANIMAL, HEMAgen BUFFY COAT, PrepIT—MAX, OMNIgene—Gut, OMNIgene Sputum, Intercept, MICRO-PLATE DOA Assays, Intercept i2, Homogeneous DOA Assays, and professional and over-the-counter Cryosurgical Systems. In addition, the company manufactures and sells oral fluid collection devices used to collect, stabilize, and store samples of genetic material for molecular testing in the consumer genetic, clinical genetic testing, academic research, pharmacogenomics, personalized medicine, and animal genetics markets. Further, it provides medical devices used for the removal of benign skin lesions by cryosurgery or freezing; various immunoassay tests and reagents for insurance risk assessment, substance abuse testing, and forensic toxicology applications; an oral fluid Western blot HIV-1 confirmatory test for confirming positive HIV-1 test; and Q.E.D. rapid point-of-care saliva alcohol test. The company sells its products to various clinical laboratories, hospitals, clinics, community-based organizations, public health organizations, research and academic institutions, distributors, government agencies, physicians’ offices, and commercial and industrial entities. OraSure Technologies, Inc. was founded in 1979 and is based in Bethlehem, Pennsylvania.

320 Employees
Last Reported Date: 03/12/15
Founded in 1979

orasure technologies inc (OSUR) Top Compensated Officers

Chief Executive Officer, President and Direct...
Total Annual Compensation: $580.1K
Chief Operating Officer, Chief Financial Offi...
Total Annual Compensation: $455.7K
Senior Vice President, General Counsel and Se...
Total Annual Compensation: $327.6K
Principal Accounting Officer, Senior Vice Pre...
Total Annual Compensation: $261.8K
Executive Vice President of Marketing and Sal...
Total Annual Compensation: $375.8K
Compensation as of Fiscal Year 2014.

orasure technologies inc (OSUR) Key Developments

OraSure Technologies, Inc. Presents at Raymond James & Associates 36th Annual Institutional Investors Conference, Mar-02-2015 11:35 AM

OraSure Technologies, Inc. Presents at Raymond James & Associates 36th Annual Institutional Investors Conference, Mar-02-2015 11:35 AM. Venue: JW Marriott Grande Lakes, 4040 Central Florida Parkway, Orlando, FL 32837, United States. Speakers: Douglas A. Michels, Chief Executive Officer, President and Director.

OraSure Technologies, Inc. Presents at Cowen and Company 35th Annual Healthcare Conference, Mar-03-2015 08:00 AM

OraSure Technologies, Inc. Presents at Cowen and Company 35th Annual Healthcare Conference, Mar-03-2015 08:00 AM. Venue: The Boston Marriott Copley Place, Boston, Massachusetts, United States. Speakers: Douglas A. Michels, Chief Executive Officer, President and Director.

Orasure Technologies Inc. Reports Unaudited Consolidated Earnings Results for the Fourth Quarter and Year Ended December 31, 2014; Provides Consolidated Earnings Guidance for the First Quarter of Fiscal 2015

OraSure Technologies Inc. reported unaudited consolidated earnings results for the fourth quarter and year ended December 31, 2014. For the quarter, the company's net revenues were $28.681 million compared with $28.768 million a year ago. Operating loss was $2.563 million compared with operating income of $6.063 million a year ago. Loss before income taxes was $2.276 million compared with income before income taxes of $6.227 million a year ago. Net loss was $2.652 million or $0.05 per basic and diluted share compared with net income of $6.213 million or $0.11 per basic and diluted share a year ago. Cash generated by operations in the fourth quarter of 2013 was $11.4 million. Net loss change in the current quarter bottom line performance was primarily the result of the absence of an $8.3 million contract termination payment received in the prior year period. Cash used by operating activities in the fourth quarter of 2014 was $858,000 compared to $11.5 million generated in the fourth quarter of 2013, which benefited from the $8.3 million payment from Roche. Consolidated product Revenue was $25.3 million decreased 12%, largely as a result of the change in revenue recognition policy related to OraQuick In-home HIV Test, which increased fourth quarter 2013 revenues by $2.5 million. For the year, the company's net revenues were $106.464 million compared with $98.94 million a year ago. Operating loss was $4.802 million compared with $12.162 million a year ago. Loss before income taxes was $4.271 million compared with $11.962 million a year ago. Net loss was $4.614 million or $0.08 per basic and diluted share compared with $11.19 million or $0.20 per basic and diluted share a year ago. The company provided consolidated earnings guidance for the first quarter of fiscal 2015. For the quarter, the company expects sales between $26.5 million and $27.0 million and consolidated net loss of approximately $0.01 to $0.02 per share. The company expects the financial impact of the upcoming pilots to be realized in second half of 2015.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
OSUR:US $6.71 USD -0.09

OSUR Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Akers Biosciences Inc $4.65 USD 0.00
Chembio Diagnostics Inc $4.58 USD -0.02
Nymox Pharmaceutical Corp $1.39 USD -0.048
Pernix Therapeutics Holdings Inc $7.09 USD -0.24
Trinity Biotech PLC $17.18 USD +0.02
View Industry Companies
 

Industry Analysis

OSUR

Industry Average

Valuation OSUR Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 3.5x
Price/Book 2.4x
Price/Cash Flow NM Not Meaningful
TEV/Sales 2.7x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact ORASURE TECHNOLOGIES INC, please visit www.orasure.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.